Today I thought it would be a good idea to answer a question sent in by a premium subscriber. He asked,
“What’s the deal with TIL and how does that relate to checkpoint inhibitors and PD-L1 expression?”
This is a good question and there were some interesting top-line debates about this at AACR recently, which are well worth discussing and highlighting.
To learn more about this emerging trend, sign in or sign up below to read our insights.